251 related articles for article (PubMed ID: 12810246)
1. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
Greenberg AS
J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
[TBL] [Abstract][Full Text] [Related]
2. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Lebovitz HE
Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
[TBL] [Abstract][Full Text] [Related]
3. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Stolar MW; Chilton RJ
Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
[TBL] [Abstract][Full Text] [Related]
4. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Després JP
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
[TBL] [Abstract][Full Text] [Related]
5. Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
Zimmet P
Trends Cardiovasc Med; 2002 Nov; 12(8):354-62. PubMed ID: 12536122
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus: a cardiovascular disease.
Candido R; Srivastava P; Cooper ME; Burrell LM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1088-94. PubMed ID: 14582453
[TBL] [Abstract][Full Text] [Related]
7. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
Meriden T
Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
[TBL] [Abstract][Full Text] [Related]
8. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.
Mikhailidis DP; Press M
Expert Opin Pharmacother; 2007 Dec; 8(17):3009-20. PubMed ID: 18001259
[TBL] [Abstract][Full Text] [Related]
9. Drug treatment of metabolic syndrome.
Altabas V
Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
[TBL] [Abstract][Full Text] [Related]
10. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
Wyne KL
Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
[TBL] [Abstract][Full Text] [Related]
11. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
Edelman SV
Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
[TBL] [Abstract][Full Text] [Related]
12. Are thiazolidinediones good or bad for the heart?
Taylor AM; McNamara CA
Curr Diab Rep; 2006 Nov; 6(5):378-83. PubMed ID: 17076999
[TBL] [Abstract][Full Text] [Related]
13. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.
Srikanth S; Deedwania P
Curr Hypertens Rep; 2016 Oct; 18(10):76. PubMed ID: 27730495
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome, inflammation and atherosclerosis.
Paoletti R; Bolego C; Poli A; Cignarella A
Vasc Health Risk Manag; 2006; 2(2):145-52. PubMed ID: 17319458
[TBL] [Abstract][Full Text] [Related]
15. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Henry RR
Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
[TBL] [Abstract][Full Text] [Related]
17. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
20. Insulin therapy for reducing cardiovascular risk in patients with type 2 diabetes.
Bohannon N
Clin Cornerstone; 2003; Suppl 4():S21-7. PubMed ID: 14986905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
